MilliporeSigma
Search Within

HPA045153

Applied Filters:
Keyword:'HPA045153'
Showing 1-12 of 12 results for "HPA045153" within Papers
Luciana Rodrigues Carvalho Barros et al.
Journal of leukocyte biology, 108(4), 1307-1318 (2020-08-23)
Esophageal squamous cell carcinoma (ESCA) exhibits high intratumoral molecular heterogeneity posing a challenge to cancer therapy. Immune checkpoint blockade therapy has been approved for this disease, but with modest results. RNA-Seq data from paired tumor and surrounding nonmalignant tissue from
Y Xu et al.
European review for medical and pharmacological sciences, 20(6), 1057-1063 (2016-04-07)
PRAME (Preferentially Expressed Antigen in Melanoma) is a tumor-associated antigen recognized by immunocytes, and it induces cytotoxic T cell-mediated responses in melanoma. PRAME is expressed in a wide variety of tumors, but in contrast with most other tumor-associated antigens, it
Aaron Y Chang et al.
The Journal of clinical investigation, 127(7), 2705-2718 (2017-06-20)
Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is expressed in many cancers and leukemias. In healthy tissue, PRAME expression is limited to the testes and ovaries, making it a highly attractive cancer target. PRAME is an
Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?
Szczepanski MJ and Whiteside TL
Biomarkers in Medicine, 7, 575-578 (2013)
Yohei Taniguchi et al.
Scientific reports, 10(1), 12286-12286 (2020-07-25)
Thymic squamous cell carcinoma (TSQCC), accounting for 70-80% of thymic carcinoma cases, is distinct from thymoma. However, differential diagnosis for type B3 thymoma is sometimes challenging, even with established markers for TSQCC, including KIT and CD5, which are expressed in ~ 80%
Wa Zhang et al.
Oncotarget, 7(29), 45352-45369 (2016-06-21)
PRAME is a cancer-testis antigen (CTA) and potential immuno-therapeutic target, but has not been well-studied in epithelial ovarian cancer (EOC) or its high grade serous (HGSC) subtype. Compared to normal ovary, PRAME expression was significantly increased most EOC, regardless of
Matthew G Field et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 22(5), 1234-1242 (2016-03-05)
Uveal melanoma (UM) can be classified by gene expression profiling (GEP) into Class 1 (low metastatic risk) and Class 2 (high metastatic risk), the latter being strongly associated with mutational inactivation of the tumor suppressor BAP1. Nevertheless, a small percentage
The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters.
Costessi A, et al.
The Embo Journal, 30, 3786-3786 (2011)
PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma.
Ercolak V, et al.
Acta Haematologica, 134, 199-207 (2015)
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene.
Gunn SR, et al.
Leukemia Research, 33, 1276-1281 (2009)
Daniel Nettersheim et al.
British journal of cancer, 115(4), 454-464 (2016-07-22)
Cancer/testis-antigens (CTAs) are specifically expressed in human malignancies and testis tissue, but their molecular functions are poorly understood. CTAs serve as regulators of gene expression, cell cycle and spermatogenesis, as well as targets for immune-based therapies. The CTA PRAME is
PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
Zhang W, et al.
Oncotarget, 7, 45352-45369 (2016)
Page 1 of 1